Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Protocol Number RPCE02D2304 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brivaracetam | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Identify lowest single oral dose producing maximal decrease or suppression of intermittent photic stimulation (IPS)photoparoxysmal response (PPR) in photosensitive epileptic subjects pre-dose | ||
| post placebo during 24h and post brivaracetam for up to 72 h |
| Measure | Description | Time Frame |
|---|---|---|
| Assess relationship between plasma concentrations and changes in photosensitivity frequency range, time of onset and duration of suppressing effect | ||
| Safety |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Philipp von Rosenstiel, MD. | UCB Pharma | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Marseille | France | |||||
Not provided
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C482793 | brivaracetam |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Paris |
| France |
| Rouen | France |
| Strasbourg | France |
| Kork | Germany |